GARAGE
Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday,
To find out more
Need help?
CALL +65 6388 3838 EMAIL btocs@sph.com.sg
Related Stories
More Stories
Crescent Cove Advisors launching special purpose acquisition company to target S-E Asian tech firms
SAN FRANCISCO-based tech investment firm Crescent Cove Advisors, founded by Singaporean Heng Jun Hong, has filed confidentially to launch a...
Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO
SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$...
Asean fintechs may list in US market on dual-listing track
SOME Asean fintechs may look to soon list in both their home markets and the US, riding on the demand for growth stocks from this part of the...